PE20011167A1 - Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna - Google Patents
Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benignaInfo
- Publication number
- PE20011167A1 PE20011167A1 PE2001000130A PE2001000130A PE20011167A1 PE 20011167 A1 PE20011167 A1 PE 20011167A1 PE 2001000130 A PE2001000130 A PE 2001000130A PE 2001000130 A PE2001000130 A PE 2001000130A PE 20011167 A1 PE20011167 A1 PE 20011167A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonist
- alpha
- adrenoreceptor
- prostatic hyperplasia
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTAGONISTA DEL ALFA-ADRENORRECEPTOR TAL COMO 4-AMINO-6,7-DIMETOXI-2-(5-METANOSULFONAMIDO-1,2,3,4-TETRAHIDROISOQUINOL-2-IL)-5-(2-PIRIDIL) QUINAZOLINA, DOXAZOSINA, TERAZOSINA, ABANOQUIL, PRAZOSINA, INDORAMINA Y b) UN ANTAGONISTA MUSCARINICO TAL COMO DARIFENACINA, TOLTERODINA Y OXIBUTININA. EL ANTAGONISTA DEL ALFA-ADRENORECEPTOR PUEDE SER NO SELECTIVO O SELECTIVO PARA EL RECEPTOR O-1 Y EL ANTAGONISTA MUSCARINICO PUEDE SER NO SELECTIVO O SELECTIVO PARA LOS RECEPTORES M3. LA COMPOSICION FARMACEUTICA ES UTIL PARA TRATAR LOS SINTOMAS DEL TRACTO URINARIO INFERIOR ASOCIADOS CON HIPERPLASIA PROSTATICA BENINGA (HPB)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18131000P | 2000-02-09 | 2000-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20011167A1 true PE20011167A1 (es) | 2001-11-13 |
Family
ID=22663745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000130A PE20011167A1 (es) | 2000-02-09 | 2001-02-07 | Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna |
Country Status (12)
Country | Link |
---|---|
US (2) | US20010044438A1 (es) |
EP (2) | EP1123705A1 (es) |
KR (2) | KR20010078803A (es) |
AU (3) | AU1832901A (es) |
CA (1) | CA2334460C (es) |
HU (1) | HU230982B1 (es) |
IL (1) | IL141235A (es) |
MY (1) | MY164900A (es) |
NZ (1) | NZ509807A (es) |
PE (1) | PE20011167A1 (es) |
TW (1) | TWI287448B (es) |
ZA (1) | ZA200101012B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
US7163696B2 (en) | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
DE20220415U1 (de) * | 2001-11-07 | 2003-10-09 | Synthon Bv | Tamsulosin-Tabletten |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
CN100355419C (zh) * | 2002-06-07 | 2007-12-19 | 安斯泰来制药有限公司 | 治疗膀胱过度活动的药物 |
WO2004017960A1 (en) * | 2002-08-14 | 2004-03-04 | Janssen Pharmaceutica N.V. | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
GB0221582D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Method of treatment |
AU2003207089A1 (en) * | 2003-02-14 | 2004-09-06 | Takeda Pharmaceutical Company Limited | Preparation for topical administration |
EP1746998A1 (en) * | 2004-03-22 | 2007-01-31 | Ranbaxy Laboratories, Ltd. | Combination therapy for lower urinary tract symptoms |
WO2005092321A1 (ja) * | 2004-03-24 | 2005-10-06 | Kissei Pharmaceutical Co., Ltd. | 頻尿または尿失禁の予防または治療用医薬組成物 |
KR100679111B1 (ko) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | 독사조신을 포함하는 서방성 정제 |
WO2007010509A2 (en) * | 2005-07-22 | 2007-01-25 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist |
US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
TW200733975A (en) * | 2005-12-20 | 2007-09-16 | Pfizer Prod Inc | Pharmaceutical combination for the treatment of luts |
WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
RU2492864C2 (ru) | 2006-09-18 | 2013-09-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения рака, несущего мутации egfr |
CA2697137A1 (en) * | 2007-07-20 | 2009-01-29 | Astellas Pharma Inc. | Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly |
US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
US7891492B2 (en) * | 2007-08-13 | 2011-02-22 | Carton Service, Incorporated | Pharmaceutical blister card package |
EP2181707A1 (en) * | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
EP2892514A4 (en) | 2012-09-05 | 2016-04-13 | Chase Pharmaceuticals Corp | Neurotropic Anticholinergic Composition and Method |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
JP7274475B2 (ja) | 2017-07-20 | 2023-05-16 | セインダ ファーマシューティカル グアンジョウ コーポレイション | 近視の処置のための組成物および方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2503059A (en) | 1950-04-04 | Nxchj | ||
US2599000A (en) | 1950-09-02 | 1952-06-03 | Smith Kline French Lab | Nu, nu-disubstituted-beta-halo-alkylamines |
IT1066857B (it) | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
IT1094076B (it) | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
GB8906166D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
US5233053A (en) | 1989-03-17 | 1993-08-03 | Pfizer Inc. | Pyrrolidine derivatives |
EP0667775A1 (en) * | 1992-11-04 | 1995-08-23 | Sepracor, Inc. | Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
US6083950A (en) * | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
WO2001021167A1 (en) * | 1999-09-22 | 2001-03-29 | Merck & Co., Inc. | Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein |
-
2001
- 2001-02-01 IL IL141235A patent/IL141235A/en active IP Right Grant
- 2001-02-05 TW TW090102380A patent/TWI287448B/zh not_active IP Right Cessation
- 2001-02-06 HU HU0100586A patent/HU230982B1/hu not_active IP Right Cessation
- 2001-02-06 ZA ZA200101012A patent/ZA200101012B/xx unknown
- 2001-02-06 MY MYPI20010519A patent/MY164900A/en unknown
- 2001-02-07 AU AU18329/01A patent/AU1832901A/en not_active Abandoned
- 2001-02-07 CA CA002334460A patent/CA2334460C/en not_active Expired - Lifetime
- 2001-02-07 EP EP01301085A patent/EP1123705A1/en not_active Withdrawn
- 2001-02-07 EP EP10179692A patent/EP2266571A1/en not_active Withdrawn
- 2001-02-07 PE PE2001000130A patent/PE20011167A1/es active IP Right Grant
- 2001-02-07 US US09/778,290 patent/US20010044438A1/en not_active Abandoned
- 2001-02-08 NZ NZ509807A patent/NZ509807A/xx not_active IP Right Cessation
- 2001-02-09 KR KR1020010006417A patent/KR20010078803A/ko active Application Filing
-
2004
- 2004-03-26 KR KR1020040020671A patent/KR20040032141A/ko not_active Application Discontinuation
-
2005
- 2005-05-31 US US11/140,723 patent/US7138405B2/en not_active Expired - Fee Related
-
2006
- 2006-05-23 AU AU2006202176A patent/AU2006202176A1/en not_active Abandoned
-
2009
- 2009-10-23 AU AU2009227918A patent/AU2009227918B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
IL141235A0 (en) | 2011-08-01 |
AU2009227918B2 (en) | 2011-09-22 |
NZ509807A (en) | 2002-09-27 |
EP2266571A1 (en) | 2010-12-29 |
AU1832901A (en) | 2001-08-16 |
US7138405B2 (en) | 2006-11-21 |
CA2334460C (en) | 2009-01-27 |
US20050222165A1 (en) | 2005-10-06 |
IL141235A (en) | 2012-04-30 |
KR20040032141A (ko) | 2004-04-14 |
HU230982B1 (hu) | 2019-08-28 |
AU2009227918A1 (en) | 2009-11-12 |
AU2006202176A1 (en) | 2006-06-15 |
TWI287448B (en) | 2007-10-01 |
HU0100586D0 (en) | 2001-03-28 |
KR20010078803A (ko) | 2001-08-21 |
MY164900A (en) | 2018-01-30 |
US20010044438A1 (en) | 2001-11-22 |
ZA200101012B (en) | 2002-08-06 |
HUP0100586A3 (en) | 2003-05-28 |
CA2334460A1 (en) | 2001-08-09 |
EP1123705A1 (en) | 2001-08-16 |
HUP0100586A2 (hu) | 2001-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20011167A1 (es) | Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna | |
Klivenyi et al. | Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity | |
ES2319886T3 (es) | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). | |
WO2006029153A3 (en) | Monocyclic anilide spirolactam cgrp receptor antagonists | |
ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
WO2002030462A3 (en) | Hedgehog antagonists, methods and uses related thereto | |
ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
ES2163293T3 (es) | Combinacion de un inhibidor de tirosina quinasas y castracion quimica para tratar el cancer de prostata. | |
YU60696A (sh) | Dihidropirimidini i njihova primena | |
TR200200928T2 (tr) | 2-pirazolin-5-on terkipleri | |
BRPI0413305A (pt) | compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1) | |
BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
MX2007005428A (es) | Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina. | |
DE602005027870D1 (de) | Cgrp-rezeptorantagonisten | |
BR0115865A (pt) | Derivados de piperazina 1,4-di-substituìda utilizáveis como bloqueadores de receptores adrenérgicos alfa1 uro-seletivos | |
PE20001299A1 (es) | Bromhidrato de eletriptan monohidratado | |
AR035600A1 (es) | Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual | |
DK1345907T3 (da) | 7-Heterocyclyl-quinolin- og thieno-2,3-B-pyridin-derivater anvendelige som antagonister af gonadotropin-frigörende hormon | |
AR029482A1 (es) | Sal de mesilato de 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil) quinazolina, forma base cristalina anhidra, formulacion farmaceutica, uso en la fabricacion de medicamentos y metodo de preparacion | |
NO20000241D0 (no) | Tricykliske vasopressin agonister | |
PE20070323A1 (es) | Composicion que comprende 4-(2,4-dicloro-5-metoxi-fenilamino)-6-metoxi-7-[3-(4-metil-piperazin-1-il)-propoxi]-quinolin-3-carbonitrilo como inhibidor de tirosina quinasa | |
SE0103858D0 (sv) | Pharmaceutical composition | |
EA200401100A1 (ru) | 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ | |
BR0214611A (pt) | Antagonistas vii de receptor ccr-3 | |
CO6140029A2 (es) | Composiciones framaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 alfa-reductasa y un antagonista de los receptores 1 alfa-adrenergicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FG | Grant, registration |